Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of ...

Dyne Therapeutics: Strong DELIVER Data Strengthens The Bull Case (NASDAQ:DYN)

Dyne Therapeutics (DYN) analysis: $1.1B cash runway to 2028, Phase 3 catalysts (DYNE-101, DYNE-251) and valuation vs peers—click to

Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of ...

New analyses out to 24-months showed improvement in heart and lung function compared to expected declines in DMD natural history

Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)

New analyses out to 24-months showed improvement in heart and lung function compared to expected declines in DMD

Dyne reports cardiopulmonary benefits in Duchenne trial of z-rostudirsen in individuals amenable to skipping exon 51

As an early investor in Dyne Therapeutics, CureDuchenne is happy to share that new analyses out to 24 months showed improvement in heart and lung function with z-rostudirsen compared to declines observed in published Duchenne natural history data.   Link to press release:  https://investors.dyne-t/news-releases/news-release-details/dyne-therapeutics-announces-new-positive-cardiopulmonary-resultsThe post Dyne reports cardiopulmonary benefits in D…